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Abstract  
Introduction: Ziehl-Neelsen (ZN) bright-field microscopy is time-consuming, with poor sensitivity, even under optimal conditions. Introduction of 
Primo Star iLED fluorescent microscopy (FM) may improve TB case finding at referral hospitals in Rwanda. The study aimed to determine the 
acceptability and effectiveness of iLED in a low resource setting. Methods: Between June 2009 and May 2010, the Rwandan TB Program and 
National Reference Laboratory carried out demonstration studies with iLED at a referral hospital in the capital, Kigali, and a rural district hospital in 
Nyamata, taking conventional FM as Gold Standard. Results: Agreement between the iLED and rechecking at the Reference Laboratory were 
deemed “almost perfect” (kappa = 0.81-1.00) across three of four site-phase combinations. The exception was Nyamata District Hospital during 
the validation phase, which was deemed “substantial” agreement (kappa = 0.61-0.80). However, the 100% concordance at both demonstration 
sites during the continuation phase shows technicians' rapid command of the new iLED microscope in a relatively short time. The lower overall 
positivity rate obtained in the rural clinic is not related to the performance of the microscope (or technicians), but is attributable to a significant 
increase in total number of patients and samples screened through active case finding. Conclusion: Laboratory technicians demonstrated high 
acceptance of iLED. Additionally, fluorescent microscopy reduces the time necessary for examination by more than half. The high level of 
agreement between iLED and FM during implementation in both sites provides initial evidence for iLED to replace current methods. 
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Introduction 
 
Sputum smear microscopy for acid-fast bacilli (AFB) using Ziehl-
Neelsen (ZN) staining remains the most cost-efficient tool available 
to diagnose tuberculosis (TB) in low-resource countries. This 
method is rapid, inexpensive, and highly specific for detecting AFB 
in high-burden settings. However, the main limitation is its low and 
variable sensitivity, exacerbated in high HIV prevalence settings [1]. 
High TB-HIV co-infection rates and low TB case detection impede 
disease control in many TB endemic settings, notably sub-Saharan 
Africa [2]. Furthermore, where workloads are high, the amount of 
time spent examining smears compromises sensitivity [3]. A recent 
systematic review demonstrated that fluorescence microscopy (FM) 
is, on average, 10% more sensitive than conventional bright-field 
microscopy in detecting AFB in clinical specimens, with comparable 
specificity, and takes significantly less time [4]. However, 
widespread implementation of FM in disease-endemic settings 
remains limited due to several factors, including the short life and 
high cost of mercury vapor lamps; difficulty in maintaining 
machines; the need for a darkroom; and strict requirements for 
electrical power supply. Light-emitting diodes (LEDs) for FM have 
been identified as an alternative to conventional FM for screening of 
AFB [5, 6]. LED lamps do not have the disadvantages of mercury 
vapor lamps, with life expectancy averaging around 50,000-100,000 
hours (10-20 years) of use [5]. They can also run on batteries 
[5, 7, 8]. Several commercial LED systems are now available, either 
as stand-alone microscopes or as add-on adapters to conventional 
microscopes [9]. Data published so far on LED microscopy for TB 
show that results in terms of sensitivity and specificity are 
comparable or better with LED than mercury vapor lamps [6, 7, 10-
13]. Study objectives: This demonstration project evaluated the 
effectiveness of employing the Primo Star iLED fluorescence 
microscope (subsequently referred to as iLED) for case finding of TB 
under routine conditions in one referral and one rural setting in 
Rwanda. Microscopists without prior experience in FM were solicited 
in order to determine operational and clinical performance, as well 
as acceptability of the technology to laboratory staff. Study 
design: This project was conducted at two sites: Nyamata district 
hospital (DH) in Bugesera district and the Centre Hospitalier 
Universitaire de Kigali (CHUK) in Kigali. Nyamata DH is a 100-bed 
hospital with a catchment area of about 300,000 people. CHUK is a 
509-bed national referral hospital (RH) serving the capital city, 
Kigali, with a catchment area of approximately 1 million people. The 
implementation of iLED was carried out in five phases: (1) ZN 
baseline; (2) iLED training and appraisal (five days); (3) validation 
(one month); (4) implementation (three months); and (5) 





Ethics statement: The evaluation was approved by the Ethical 
Review Committee of the Ministry of Health (Kigali, Rwanda) under 
Protocol Number 58/RNEC/2009 and by the Institutional Review 
Board of Columbia University IRB-AAAC6248 (New York, NY, USA). 
Written consent was not obtained because microscopy for AFB 
smears is the standard of care in Rwanda as part of regular clinic 
monitoring and evaluation of Tuberculosis. During validation, all 
sputum results obtained though iLED were rechecked systematically 
by the National Reference Laboratory before results were provided 
to patients for management. The implementation phase was only 
allowed once iLED was validated as a replacement for light 
microscopy with similar or better sensitivity, therefore not placing 
patients at risk of misdiagnosis. Written consent to participate in the 
study was not sought from the microscopists or their supervisors 
because the introduction of the iLED only minimally increased the 
workload and only for a short duration (1 month) during the whole 
study. Participants were informed about the purpose and impact of 
the study, and microscopists readily participated enthusiastically. 
The need for collecting documented informed consent was waived 
by the IRB. Phase 1: ZN Baseline: The aim of this one-month 
phase was to establish a baseline, under study conditions, of false 
positivity and negativity rates for ZN. TB treatment decisions were 
based on ZN results. All incoming sputum smears were stained for 
ZN examination under routine conditions. Slides were read using the 
available conventional bright-field microscope (1000x). After 
reading, all slides were kept in slide boxes, which were labeled to 
specify the study phase, study site, box number, and slide ID. Once 
every two weeks, the National Reference Laboratory (NRL) study 
supervisor collected all boxes. NRL study technicians rechecked all 
slides using conventional bright-field microscopes. Discrepant slides, 
if any, were sent to the Supra National Reference Laboratory (SNRL) 
in Germany for rereading. Phase 2: Training and Appraisal: A 
standardized five-day training course for microscopists and 
supervisors participating in the study was conducted. All eight 
participants had skills in ZN microscopy but not conventional FM. 
Participants after learning the purpose and impact of the study, 
participated readily. Following the training, all technicians involved 
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in the project filled out a questionnaire about several features of the 
iLED, including installation and first use, training, and optics and 
handling. Phase 3: validation: The validation phase lasted one 
month. Each sputum sample at the study sites was stained using 
Auramine O and examined by the iLED at 400x magnification. 
Patient management was based solely on the rechecking results 
carried out by the NRL. Staining solutions were prepared by NRL 
using Merck staining reagents (Catalogue 41000, Auramine O, item 
number 1013010050, lot number ZC 253201532) and provided to 
the study sites once per month, taking into consideration the limited 
shelf life of Auramine O. All readings (including rechecking) were 
done within 48 hours of staining. Results were quantified according 
to the scale presented in Table 1. NRL rechecked all slides using 
conventional FM. Rechecked results were provided to study sites the 
next day for timely patient management. The semi-quantitative 
scale for rechecking by NRL was different than the one used by 
study sites (Table 2). Discordant slides, if any, were sent to the 
SNRL for final discussion. The study sites were allowed to proceed 
to phase four only if the following performance targets were met: 
(1) 95% accordance between validation results of microscopy center 
and supervisory site; (2) quality of Auramine O stains acceptable in 
100% of slides examined; and (3) fewer than two false results in a 
proficiency testing panel of 10 pre-defined slides. 
  
Phase 4: implementation phase: The procedures were the same 
as during the validation phase. The duration of this phase was three 
months, and patient management was now based on iLED results. 
Supervision and rechecking by the NRL study supervisor were 
carried out using Lot Quality Assurance Sampling (LQAS). The 
sample size was calculated by NTP/NRL based on the positivity and 
number of negative smears, but the frequency of rechecking was 
decreased from daily to once every two weeks. Rereading by NRL 
was done using conventional FM at 400x magnification. Discordant 
slides, if any, were sent to the SNRL in Germany for umpire reading. 
Rechecked results were provided to study sites. Phase 5: 
continuation and expansion: The continuation phase lasted six 
months, and patient management was based on iLED results. 
Supervision and rechecking by NRL supervisors was carried out 
according to national Rwandan External Quality Assurance 
guidelines. Fifteen slides were collected quarterly and rechecked by 
NRL using conventional FM at 400 x magnification. Discordant 
slides, if any, were sent to the SNRL in Germany for umpire reading. 
Rechecked results were provided to study sites. After the six-month 
continuation phase, and following the availability of the compiled 
results of the previous phase, the demonstration project coordinator 
allowed all sites to use the iLED method routinely under program 
conditions. Data entry and analysis: All data and results were 
recorded in phase-specific forms and sent to NRL and NTP. An 
electronic database was completed on-site. Positivity agreement 
between methods at the study laboratories (DH or CHUK) and the 
National Reference Laboratory was assessed using Cohen's Kappa, 
which corrects for agreement by chance. Strength of agreement 
was evaluated using guidelines from Land is and Koch [14]: <0 = 
poor; 0-0.20 = slight; 0.21-0.40 = fair; 0.41-0.60 = moderate; 





Baseline: At the DH in Nyamata, all incoming sputum samples 
(100) from 37 patients, using the Spot-Morning-Spot criteria, were 
examined using ZN staining during the baseline phase. The 
positivity rate of the slides was 11% (11/100 -Table 3) with only 
one low false positive (LFP) as determined following rechecking. The 
LFP result had no negative public health consequence on the 
accurate diagnosis of the patient. There were no poorly stained 
slides reported by the NRL. At CHUK in Kigali, all incoming sputum 
samples (205) from 94 patients (Spot-Morning-Spot) were analyzed. 
The positivity rate for the samples was 7.3% (15/205 - Table 4) 
and two quantification errors (QEs) were reported following 
rechecking at NRL. The two QEs, corresponding to two samples 
from two different patients, had no negative public health 
consequence. There were no poorly stained slides reported by the 
NRL for CHUK during the rechecking of the baseline. For the 
comparison between results obtained by the DH in Nyamata and the 
NRL, Kappa was 0.947 [95% CI: 0.84, 1.00], which indicates an 
almost perfect agreement between the two laboratories (see results 
in Table 5). For the comparison between CHUK and NRL, Kappa 
was 1.000 due to full agreement (Table 5). 
  
Validation phase: In Nyamata, all incoming samples (100) from 
39 patients were screened. The positivity rate decreased to 4% 
(4/100 - see Table 3) and there were 1 low false positive and 1 low 
false negative (LFN) errors reported. Additionally, 15 samples were 
reported as having poor stains. The LFN and LFP errors, 
corresponding to two samples from the same patient, would not 
have a negative public health consequence and were probably due 
to administrative errors. However, as per protocol, diagnosis was 
made solely on the basis of the rechecking by the NRL. Kappa was 
Page number not for citation purposes 4 
0.740 [95% CI: 0.38, 1.00], which indicates substantial agreement 
between the laboratories (Table 5). In CHUK, all incoming samples 
(202) from 87 patients were screened. The positivity rate 
significantly increased from baseline to 22.3% (45/202 - see Table 
4) and there was one LFN reported. Since only one sample was 
collected for that particular patient, the LFN error would have had a 
negative public health consequence on the accurate diagnosis of the 
patient. The patient was adequately treated following rechecking by 
NRL. Nine samples were reported as having poor stains by the NRL. 
Kappa was 0.986 [95% CI: 0.96, 1.00'> 1.00], which indicates an 
almost perfect agreement between laboratories (Table 5). No 
errors were detected at the proficiency panel test. Both sites were 
allowed to proceed to the implementation phase. 
  
Implementation phase: In Nyamata, following LQAS, 44 samples 
(corresponding to 44 patients) were rechecked by the NRL study 
supervisor. The positivity rate for samples increased from validation 
to 9.1% (4/44) but remained lower than in the baseline phase 
(Table 3). No reading/diagnosis errors were reported by the NRL. 
However, there were six poorly stained samples. Kappa was 1.000 
due to full agreement (Table 5). In CHUK, following LQAS, 45 
samples from 45 patients were rechecked. The positivity rate for 
samples increased further from baseline and validation to 31.1% 
(14/45), as shown in Table 4. Only one LFN and three poor stains 
were reported by the NRL. It is not possible to say whether the LFN 
error had a negative public health consequence, since the other two 
samples from this particular patient were not rechecked and could 
have been positive. Kappa was 0.949 [95% CI: 0.85; 1.00], which 
indicates an almost perfect agreement between laboratories (Table 
5). 
  
Continuation phase: In Nyamata, 16 samples were read from 
January through March by iLED at the site and conventional FM at 
NRL, and 100% concordance was observed. From April through 
June, an additional 11 samples were rechecked and all results 
concurred. At CHUK, there were 15 samples screened from January 
through March and 100% concordance was observed. Sixteen 
additional samples were screened from April through June and 
100% concordance was also observed. Technicians' appraisal: 
the appraisal took place after training of the 
technicians. Installation and first use: All technicians felt that 
installation of the iLED was easy and that the manual was 
comprehensive and easy to read and understand. Training: The 
technicians participating in the iLED project felt that for technicians 
already trained in ZN microscopy (such as themselves), an iLED 
training of 1-5 days was suitable. However, for technicians not 
familiar with ZN microscopy, an iLED training of 3-20 days was 
suitable. Technicians also felt that NTPs can readily use the current 
manual developed by the manufacturer for implementation of LED 
microscopy without major changes. 
  
Optics and handling: All technicians were satisfied with the 
contrast, color, intensity, and signal-to-noise ratio of the iLED. All 
technicians were very satisfied with the resolution and depth of 
focus of the iLED. All technicians also felt that the field of view of 
the iLED is more homogenously illuminated compared to the 
standard view. All of them were very satisfied with the overall 
handling features of the microscope. All technicians also felt that it 
was convenient or very convenient to switch between bright field 
and fluorescence. Only one technician surveyed felt that the toggle 
field was not robust. All technicians felt that no darkroom was 
needed when using iLED, a really convenient feature of iLED 
compared to regular FM. All technicians also agreed that the 
dazzling protection for the eyepieces was useful. None of the 






Compared to classical FM with mercury vapor lamp, LED FM is more 
user-friendly and benefits from a high acceptability by technicians. 
Microscopes do not require warm-up and cool-down time, a 
considerable advantage when power supply is erratic, and the LED 
light source is considered safer than the mercury vapor lamp. LED 
systems developed for AFB smears consist either of modules that 
can be fitted to a conventional microscope, or a complete 
microscope with built-in LED as the light source, such as the iLED. 
While Partech (Münster, Germany) and Cytoscience (Fontaines, 
Switzerland) have both developed complete LED FM microscopes, 
these microscopes are less appropriate for TB than iLED since they 
are monocular. Using a camera and monitor might be an 
appropriate solution, but not in less-developed countries. iLED, a 
binocular FM microscope with built-in LED lamp for epi-fluorescence 
has produced very good results in reference laboratories [13]. So 
far, very few reports on these systems exist. These rare reports, 
however, show excellent performance compared to ZN microscopy 
[15, 16]. Our study is the first direct evaluation of iLED in Rwanda. 
LED add-on kits have been designed for different common types of 
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bright field microscopes. The complete installation is not difficult, 
but it requires slightly more time and care, which could be a 
disadvantage from the end-user perspective. As difficulty in 
acceptance by inexperienced microscopists seems to be the main 
obstacle to the use of FM outside referral laboratories, this may 
prove to be a major advantage of transmitted LED light FM, as 
reported earlier from Tanzania [8]. It also remains to be seen 
whether complete binocular LED microscopes using epi-
fluorescence, rather than transmitted light, will meet the same 
acceptance level with the progressive decentralization of FM to 
peripheral hospitals and health centers. Our study shows that the 
acceptability amongst the staff using iLED was extremely high and 
proficiency in adequate usage was rapid. Compared to traditional 
bright-field methods, LED fluorescence methods using Auramine O 
staining allows up to four times faster screening. The detection rate 
is also estimated to be at least 10% higher. While we did not 
directly compare the positivity rates between ZN and iLED, we 
monitored the positivity rate over time during our study. 
  
In Nyamata, the positivity rate surprisingly decreased during the 
validation phase (Table 5). This result compares with previously 
established data from the National TB Programme, which has shown 
that in the last quarter of 2009 and first quarter of 2010, during 
which our study took place, there was an overall decrease in 
positivity rate that is not related to the performance of the 
microscope (or the technicians) but is rather attributable to a 
significant increase in total number of patients and samples 
screened. Indeed, the positivity rate dropped to 7.7% during our 
study, compared to 9.2% the year before. This increase in the total 
number of patients screened may be the result of the impact of 
Community Health Workers (CHWs) in Bugesera District (where 
Nyamata DH is located), who have been involved in active case 
finding, therefore casting a wider net for overall screening of TB 
suspects and decreasing the positivity rate at the Nyamata Center. 
One of the expected issues associated with the change from ZN to 
Auramine staining for the purpose of our study was a difficulty in 
preparing and then subsequently reading the slides adequately 
using the Auramine protocol. Indeed, a few of the smears in the 
various phases were reported as having poor stains. We believe 
these could be explained by the fact that some laboratory 
technicians were not completely proficient in staining the slides 
appropriately, as can also sometimes be the case for ZN. However, 
this was not an issue throughout the study as the number of slides 
poorly stained gradually decreased at both sites. Agreement 
between the iLED and rechecking at the Reference Laboratory were 
deemed “almost perfect” (kappa = 0.81-1.00) across three of four 
site-phase combinations. The exception was Nyamata District 
Hospital during the validation phase, which was deemed 
“substantial” agreement (kappa = 0.61-0.80). However, the 100% 
concordance at both demonstration sites during the continuation 
phase shows technicians' rapid command of the new iLED 
microscope in a relatively short time. Technicians can therefore be 
easily trained to switch from ZN microscopy to LED FM with a high 
success rate. This should be of interest to national TB control 
programs that are interested in improving their overall case 
detection rate but cannot yet invest in the newer, molecular-based 





In our study, the use of iLED FM module in both a referral hospital 
and rural clinic setting was associated with a high concordance rate 
as compared to a Reference Laboratory using conventional FM. The 
high level of agreement between iLED and FM during our study in 
multiple sites, combined to the fact that fluorescent microscopy 
reduces the time necessary for examination by more than half, 
provides initial evidence for the iLED to replace current standard 
methods. The iLED microscope also excelled in terms of user-
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Table 1: Semi-quantitative scale used for reading with iLED 
IUATLD Scale (1000field =HPF) 
Result 
iLED (400x magnification: 1 length =40 fields = 200HPF 
Negative Zero AFB /1 length 
Scanty 1–19 AFB/1 length 
1+ 20–199 AFB/1 length 
2+ 5–50 AFB/1 field on average 




Table 2: Semi-quantitative scale for rechecking with conventional FM 
IUATLD Scale (1000field =HPF) 
Result 
Conventional FM (200-250x magnification: 1 length 
=30 fields = 300HPF 
Negative Zero AFB /1 length 
Scanty 1–9 AFB/1 length 
1+ 30–299 AFB/1 length 
2+ 10–100 AFB/1 field on average 




Table 3: Distribution of slides by outcome at different phases of the study evaluation at Nyamata Hospital 
Quantification Negative Positive Scanty Total %Positive 
Baseline 89 8 3 100 11.0% 
Validation 96 1 3 100 4.0% 
Implementation 40 3 1 44 9.1% 
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Table 4: Distribution of slides by outcome at different phases of the study evaluation at CHUK 
Quantification Negative Positive Scanty Total %Positive 
Baseline 190 14 1 205 7.3% 
Validation 157 25 20 202 22.3% 
Implementation 31 12 2 45 31.1% 




Table 5: Statistical analysis of diagnostic outcomes by site at Nyamata District Hospital (DH) 
and at the Centre Hospitalier Universitaire de Kigali (CHUK) by either LM or iLED 





DH Baseline LM 100 1.000 0.989 0.947 [0.84, 1.00] 
CHUK Baseline LM 205 1.000 1.000 1.000 [1.00, 1.00] 
DH Validation iLED 100 0.750 0.990 0.740 [0.38, 1.00] 
CHUK Validation iLED 202 0.978 1.000 0.986 [0.96, 1.00] 
DH Implementation iLED 44 1.000 1.000 1.000 [1.00, 1.00] 
CHUK Implementation iLED 45 0.933 1.000 0.949 [0.85, 1.00] 
 
